When viral footage surfaced in China showing an Alzheimer’s patient briskly walking eight months after undergoing experimental neck surgery, desperate families rushed to seek the procedure. By May 2025, an estimated 2,000 patients had undergone deep cervical lymphovenous anastomosis (DCLVA) across roughly 300 hospitals, often paying tens of thousands of dollars to plastic surgeons for a procedure with virtually no proven clinical efficacy. The surge in unverified treatments eventually forced China’s National Health Commission to step in and ban the operation outside formal clinical research settings.
The surgical procedure, originally adapted from a treatment for chronically swollen limbs by surgeon Xie Qingping, attempts to enhance the brain’s waste drainage system. By connecting lymphatic vessels in the neck to nearby veins, proponents claim DCLVA accelerates the clearance of toxic protein clumps—such as beta-amyloid and tau—associated with cognitive decline in Alzheimer’s disease. However, neuroscientists have expressed deep skepticism over the lack of rigorous evidence supporting the intervention, noting that single patient videos fail to establish scientific validity or account for placebo effects.
While antibody therapies like lecanemab exist to target amyloid plaques, their astronomical costs and requirement for repeated infusions make them inaccessible for many. The prospect of a one-time surgical intervention remains alluring, prompting small early-phase safety trials in Singapore and the United States. Although initial findings presented at the Alzheimer’s Association International Conference suggested short-term safety over six months and minor cognitive signals in isolated cases, experts emphasize that these unblinded, uncontrolled studies cannot confirm therapeutic benefit.
Currently, a randomized controlled trial in China comparing DCLVA against a sham procedure aims to provide definitive answers. Yet the study has ignited fierce ethical debate among international researchers, who question whether subjecting frail, elderly dementia patients to invasive "fake" surgery under general anesthesia can be justified. As researchers worldwide closely monitor forthcoming clinical trial data, medical authorities continue to stress that experimental procedures must not bypass rigorous scientific validation, no matter how desperate the search for a cure may be.